Company profile
GENELUX CORP
NASDAQ:GNLXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OLVIMULOGENE NANIVACIREPVEC | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01443260 | phase1_2 | completed | 2012-02-01 | 2014-09-01 | Genelux GmbH | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis |
| NCT05281471 | phase3 | recruiting | 2022-08-31 | 2026-12-01 | Genelux Corporation | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| NCT06463665 | phase2 | recruiting | 2024-09-26 | 2027-02-01 | Genelux Corporation | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer |
| NCT02759588 | phase1_2 | completed | 2016-05-01 | 2021-12-31 | Genelux Corporation | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer |
| NCT01584284 | phase1 | completed | 2012-04-01 | 2015-06-01 | Genelux Corporation | Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer |
FDA applications (0)
No records yet.